GTC Biotherapeutics (fka GTCB)

[croumagnon]

the phase-2b in RA (data expected soon)

Aren't they a bit behind the original guidance on that? Perhaps I am wrong but I thought that data was expected in late spring early summer.

Otherwise, GTCB currently is one of the safest bets in the market and I am surprised we are still trading below $2. I am also surprised that a hostile takeover attempt has not happened at these oversold prices...